Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of novel immunotherapy combinations in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
jRCT2031230371Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of dostarlimab, belrestotug, nelistotug and remzistotug in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by GSK. Primary endpoint: Antitumor activity. Started Nov 2023; status: active, not recruiting.
02
Drugs
dostarlimabbelrestotugnelistotugremzistotug
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031230371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230371.